Testosterone Treatment and the Risk of Prostate Adverse Events

• Jason A. Levy ^[1] ; Arthur L. Burnett ^[2] ; Adrian S. Dobs ^[3]
  1. [1] Johns Hopkins School of Medicine Brady Urological Institute, 600 North Wolfe Street Park 2, Baltimore, MD 21287, USA
  2. [2] Johns Hopkins School of Medicine Brady Urological Institute, 600 North Wolfe Street, Marburg 407, Baltimore, MD 21287, USA
  3. [3] Johns Hopkins Clinical Research Network, 1830 Monument Street, Suite 328, Baltimore, MD 21205, USA

  Mostrar afiliaciones +
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 51, Nº. 1, 2022, págs. 123-131
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hypogonadism is a common clinical condition affecting men, with older men having an increased incidence. Clinicians (endocrinologists and urologists) who may be involved in providing testosterone therapy should be familiar with the effects of testosterone on the prostate. Before initiating testosterone therapy, physicians and patients should partake in shared decision-making, including pretreatment testing, risks and benefits of testosterone therapy relating to benign prostatic hyperplasia and lower urinary tract symptoms, a discussion on prostate cancer in those who have not been diagnosed with malignancy, and a thorough discussion with patients who may have a previous diagnosis of prostate cancer.